Home - National Multiple Sclerosis Society

Skip to navigation Skip to content

Companies Launch Marketing Of TysabriŽ For Relapsing MS
Drug Now Available

July 18, 2006—Biogen Idec and Elan Pharmaceuticals have now commercially launched TysabriŽ (natalizumab) in the U.S. Tysabri was approved by the FDA in June for relapsing multiple sclerosis. The companies are sending out letters and emails announcing this fact to healthcare professionals and to people with MS who had requested updates on Tysabri. Read more

webcast icon Webcasts
(transcripts available)

MS Learn Online presents
Tysabri: What You Need To Know

The Basic Facts

A Look at the Infusion Process

Learn more about these and other webcasts

Background on TysabriŽ

TysabriŽ (natalizumab, sponsored by Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody given by infusion into a vein every four weeks. This drug was on the market for four months as a therapy for relapsing MS until it was withdrawn from the market in February 2005 due to safety concerns.

InsideMS: Special Report Voices of Hope and Determination
People with MS impact Tysabri recommendation

An open letter to the membership of the National Multiple Sclerosis Society from Joyce Nelson, President & CEO. (PDF)

See also...

  Last updated January 28, 2008